Vitura Health (ASX:VIT) - Hisse Senedi Fiyatı, Haberler ve Analizler

Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

VIT Stoklara Genel Bakış

Vitura Health Limited, Avustralya'da tıbbi kenevir ürünlerinin satışı ve dağıtımı ile ilgilenmektedir.

VIT temel anali̇z
Kar Tanesi Skoru
Değerleme	4/6
Gelecekteki Büyüme	0/6
Geçmiş Performans	2/6
Finansal Sağlık	6/6
Temettüler	0/6

Ödüller

Adil değer tahminimizden 50.7% daha düşük bir oranda işlem görüyor

Risk Analizi

Anlamlı bir piyasa değeri yok ( A$42M )

Kar marjları (2.8%) geçen yılın (11.8%) altında

Hissedarlar geçen yıl sulandırıldı

Son 3 ayda önemli miktarda içeriden satış gerçekleşti

Vitura Health Limited Rakipler

ECS Botanics Holdings

ASX:ECS

AU$23.2m

Vita Life Sciences

ASX:VLS

AU$126.1m

Cryosite

ASX:CTE

AU$39.0m

Neuren Pharmaceuticals

ASX:NEU

AU$1.9b

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Vitura Health
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	AU$0.073
52 Haftanın En Yüksek Seviyesi	AU$0.39
52 Haftanın En Düşük Seviyesi	AU$0.068
Beta	0.16
11 Aylık Değişim	-8.75%
3 Aylık Değişim	-22.34%
1 Yıllık Değişim	-78.53%
33 Yıllık Değişim	-57.06%
5 Yıllık Değişim	n/a
Halka arzdan bu yana değişim	-78.53%

Son Haberler & Güncellemeler

Vitura Health's (ASX:VIT) Soft Earnings Don't Show The Whole Picture

Sep 07

Vitura Health Limited's (ASX:VIT) 26% Dip In Price Shows Sentiment Is Matching Earnings

Aug 12

Recent updates

Vitura Health's (ASX:VIT) Soft Earnings Don't Show The Whole Picture

Sep 07

Vitura Health Limited's (ASX:VIT) 26% Dip In Price Shows Sentiment Is Matching Earnings

Aug 12

Vitura Health Limited (ASX:VIT) Looks Inexpensive After Falling 26% But Perhaps Not Attractive Enough

Aug 12

The Market Doesn't Like What It Sees From Vitura Health Limited's (ASX:VIT) Earnings Yet As Shares Tumble 43%

Apr 25

Does Vitura Health (ASX:VIT) Have A Healthy Balance Sheet?

Apr 11

Investors Don't See Light At End Of Vitura Health Limited's (ASX:VIT) Tunnel And Push Stock Down 37%

Feb 27

Here's Why We Think Vitura Health (ASX:VIT) Is Well Worth Watching

Feb 25

Calculating The Fair Value Of Vitura Health Limited (ASX:VIT)

Dec 13

Here's Why Shareholders Will Not Be Complaining About Vitura Health Limited's (ASX:VIT) CEO Pay Packet

Nov 21

Is Now The Time To Put Vitura Health (ASX:VIT) On Your Watchlist?

Nov 01

Here's Why We Think Vitura Health (ASX:VIT) Is Well Worth Watching

Jul 18

Earnings Not Telling The Story For Cronos Australia Limited (ASX:CAU) After Shares Rise 111%

Sep 12

If EPS Growth Is Important To You, Cronos Australia (ASX:CAU) Presents An Opportunity

Sep 05

Hissedar Getirileri

	VIT	AU Pharmaceuticals	AU Pazar
7D	0%	3.8%	1.1%
1Y	-78.5%	98.5%	17.9%

Getiri vs. Endüstri: VIT geçen yıl % 98.5 oranında getiri sağlayan Australian Pharmaceuticals sektörünün gerisinde kaldı.

Getiri vs Piyasa: VIT geçen yıl % 17.9 oranında getiri sağlayan Australian Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is VIT's price volatile compared to industry and market?
VIT volatility
VIT Average Weekly Movement	12.2%
Pharmaceuticals Industry Average Movement	10.4%
Market Average Movement	9.0%
10% most volatile stocks in AU Market	17.6%
10% least volatile stocks in AU Market	3.6%

İstikrarlı Hisse Senedi Fiyatı: VIT hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.

Zaman İçindeki Volatilite: VIT 'nin haftalık oynaklığı ( 12% ) son bir yıldır istikrarlı seyretti.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2018	n/a	Tom Howitt	vitura.com.au

Vitura Health Limited, Avustralya'da tıbbi kenevir ürünlerinin satışı ve dağıtımı ile ilgilenmektedir. İki segment üzerinden faaliyet göstermektedir: Satış ve Dağıtım; ve Klinikler ve Hizmetler. Şirket, alternatif tedaviler için reçeteleme, dağıtım ve ilaç yönetimi çözümleri sunan çevrimiçi bir platform olan CanView'ı; isteğe bağlı sanal sağlık hizmetlerinin önde gelen sağlayıcısı olan Doctors on Demand'ı; alternatif bir tedavi distribütörü olan BHC'yi; tıbbi konsültasyon ve reçete hizmetleri sunan CDA Clinics'i ve tele-sağlık konsültasyonları sunan bir tıbbi kenevir kliniği olan Cannadoc'u işletmektedir.

Vitura Health Limited Temel Bilgiler Özeti

Vitura Health'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
VIT temel i̇stati̇sti̇kler
Piyasa değeri	AU$42.04m
Kazançlar(TTM)	AU$3.51m
Gelir(TTM)	AU$123.87m

12.0x

F/K Oranı

0.3x

P/S Oranı

VIT aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
VIT gelir tablosu (TTM)
Gelir	AU$123.87m
Gelir Maliyeti	AU$89.65m
Brüt Kâr	AU$34.22m
Diğer Giderler	AU$30.71m
Kazançlar	AU$3.51m

Son Raporlanan Kazançlar

Jun 30, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	0.0061
Brüt Marj	27.63%
Net Kâr Marjı	2.84%
Borç/Özkaynak Oranı	13.8%

VIT uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

VIT Stoklara Genel Bakış

Ödüller

Risk Analizi

Vitura Health Limited Rakipler

ASX:ECS

AU$23.2m

ASX:VLS

AU$126.1m

ASX:CTE

AU$39.0m

ASX:NEU

AU$1.9b

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Vitura Health Limited Appoints Stefan Schmidt as Chief Technology Officer

Vitura Health's (ASX:VIT) Soft Earnings Don't Show The Whole Picture

Vitura Health Limited, Annual General Meeting, Nov 27, 2024

Full year 2024 earnings released: EPS: AU$0.006 (vs AU$0.025 in FY 2023)

Vitura Health Limited Resolves Not to Pay A Dividend in Respect of the Year Ended 30 June 2024

Vitura Health Limited's (ASX:VIT) 26% Dip In Price Shows Sentiment Is Matching Earnings

Recent updates

Vitura Health Limited Appoints Stefan Schmidt as Chief Technology Officer

Vitura Health's (ASX:VIT) Soft Earnings Don't Show The Whole Picture

Vitura Health Limited, Annual General Meeting, Nov 27, 2024

Full year 2024 earnings released: EPS: AU$0.006 (vs AU$0.025 in FY 2023)

Vitura Health Limited Resolves Not to Pay A Dividend in Respect of the Year Ended 30 June 2024

Vitura Health Limited's (ASX:VIT) 26% Dip In Price Shows Sentiment Is Matching Earnings

Vitura Health Limited (ASX:VIT) Looks Inexpensive After Falling 26% But Perhaps Not Attractive Enough

Less than half of directors are independent

Board Member recently sold AU$1.1m worth of stock

The Market Doesn't Like What It Sees From Vitura Health Limited's (ASX:VIT) Earnings Yet As Shares Tumble 43%

New major risk - Share price stability

Does Vitura Health (ASX:VIT) Have A Healthy Balance Sheet?

First half 2024 earnings released: EPS: AU$0.006 (vs AU$0.014 in 1H 2023)

Investors Don't See Light At End Of Vitura Health Limited's (ASX:VIT) Tunnel And Push Stock Down 37%

Now 39% undervalued after recent price drop

Here's Why We Think Vitura Health (ASX:VIT) Is Well Worth Watching

Calculating The Fair Value Of Vitura Health Limited (ASX:VIT)

Vitura Health Limited Receives Shareholder Requisition from Elizabeth Sarah Jansen

Here's Why Shareholders Will Not Be Complaining About Vitura Health Limited's (ASX:VIT) CEO Pay Packet

Is Now The Time To Put Vitura Health (ASX:VIT) On Your Watchlist?

Vitura Health Limited (ASX:VIT) completed the acquisition of acquire an unknown stake in Doctors on Demand from Yeates Ventures Pty Ltd and Kirsty Garrett.

New minor risk - Shareholder dilution

Vitura Health Limited, Annual General Meeting, Nov 28, 2023

Upcoming dividend of AU$0.01 per share at 2.7% yield

Vitura Health Limited Announces Dividend for the Year Ended 30 June 2023, Payable on or Around, 28 September 2023

New major risk - Earnings quality

New minor risk - Financial data availability

Here's Why We Think Vitura Health (ASX:VIT) Is Well Worth Watching

Insider recently sold AU$2.3m worth of stock

New minor risk - Share price stability

Chief Commercial Officer recently sold AU$5.9m worth of stock

High number of new and inexperienced directors

Cronos Australia Limited Announces Changes to Clinical Operations

High number of new and inexperienced directors

High number of new and inexperienced directors

Cronos Australia Limited Announces Board Changes

High number of new and inexperienced directors

High number of new and inexperienced directors

Cronos Australia Limited Announces Ceases of Benjamin D.N. Jansen as Chief Medical Officer

Cronos Australia Limited Provides Update on Canview 2.0 Platform

Cronos Australia Limited, Annual General Meeting, Nov 29, 2022

Earnings Not Telling The Story For Cronos Australia Limited (ASX:CAU) After Shares Rise 111%

Cronos Australia Limited Appoints Jenelle Frewen and Simone Scovell as Independent Non-Executive Director

If EPS Growth Is Important To You, Cronos Australia (ASX:CAU) Presents An Opportunity

Cronos Australia Limited Announces Dividend for the Year Ended 30 June 2022, Dividend Payment Date Is 11 October 2022

Full year 2022 earnings released: EPS: AU$0.013 (vs AU$0.031 loss in FY 2021)

Cronos Australia Limited to Report Q2, 2022 Results on Jul 27, 2022

Cronos Australia Announces Resignation of Shane Tanner, Chairman and Director

Cronos Australia Limited Announces Resignation of Kurt Thomas Schmidt as Director

First half 2022 earnings: Revenues and EPS in line with analyst expectations

High number of new directors

Cronos Australia Limited (ASX:CAU) completed the acquisition of Cannabis Doctors Australia Pty Ltd.

Cronos Australia Limited (ASX:CAU) entered into Merger implementation agreement to acquire Cannabis Doctors Australia Pty Ltd.

Cronos Australia Limited Announces Launch of Additional Products in Key Asian Markets

Cronos Australia Limited Provides Revenue Guidance for the Fourth Quarter of 2021

Cronos Australia Limited Announces Launch of First Personal Care Brand in North Asian Markets with Bathing Shed

Hissedar Getirileri

Fiyat Oynaklığı

Şirket Hakkında